Mechanism of Action
Opposing Nociceptin/N-OFQ
Nociceptin/N-OFQ acting at NOP receptors produces spinal hyperalgesia, allodynia, and blocks morphine analgesia. Nocistatin, from the same prepronociceptin precursor, blocks N/OFQ-induced hyperalgesia and allodynia when given intrathecally. Nocistatin does not appear to compete at NOP receptors; its mechanism may involve inhibiting PKC-epsilon translocation (which is required for N/OFQ to produce allodynia) or acting at a distinct nocistatin receptor not yet characterized.
Independent Antinociceptive Effects
Beyond blocking N/OFQ actions, nocistatin has independent antinociceptive properties at higher doses in inflammatory pain models. Spinal nocistatin reduces carrageenan-induced hyperalgesia and formalin pain behaviors. Central (ICV) nocistatin in supraspinal circuits can also modulate fear and anxiety-related behaviors, suggesting broader neuromodulatory roles.
Research Summary
Spinal Pain Modulation
PreclinicalIntrathecal nocistatin produces dose-dependent antinociception in hot plate and writhing tests and blocks N/OFQ-induced hyperalgesia. Inflammatory pain models (carrageenan paw inflammation, CFA arthritis): nocistatin reduces mechanical and thermal hyperalgesia. The PNOC gene products (N/OFQ + nocistatin) may represent an endogenous pain-modulating yin-yang system.
Anxiety and Memory
PreclinicalICV nocistatin at low doses reduces anxiety in elevated plus-maze and fear conditioning tests in rodents, opposite to the anxiolytic N/OFQ profile at the same doses. Nocistatin effects on memory consolidation are distinct from N/OFQ. The nocistatin/nociceptin ratio in specific brain regions may govern the behavioral output of the PNOC system.
Calculate your Nocistatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Spinal pain research | 0.1-10 nmol intrathecal (rodent) | Per session | Intrathecal |
| N/OFQ blockade research | Nocistatin pre-treatment at 0.1-1 nmol IT, then N/OFQ 0.1-1 nmol IT | Per session | Intrathecal |
Nocistatin and nociceptin co-release from PNOC-expressing neurons complicates in vivo interpretation. Study nocistatin effects in isolation using synthetic peptide or PNOC knockout comparisons.
Interactions
Safety Profile
No human safety data. Research doses in animals produce antinociception and modest sedation at high doses. No significant adverse effects reported in preclinical studies. Peptide is rapidly degraded, limiting duration of action and systemic accumulation. The opposing mechanism to nociceptin suggests that nocistatin agonism would reduce pain sensitization rather than produce new adverse effects. No cardiovascular, hepatic, or reproductive toxicity identified in acute studies.
References
- [1]Okuda-Ashitaka E, et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature. 1998;392(6673):286-289.
- [2]Yamamoto T, et al. Characterization of nocistatin-mediated pain modulation. Eur J Pharmacol. 2000;400(2-3):141-148.